FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
The FDA has approved a higher 7.2 mg dose of Wegovy (semaglutide) injection. This new dosage is indicated for weight loss and long-term maintenance of weight loss in certain adult patients.
Manufacturers of GLP-1 receptor agonists, specifically Novo Nordisk, as well as regulatory and pharmacovigilance departments managing metabolic health portfolios.
This approval expands the available therapeutic range for semaglutide in weight management. From a regulatory perspective, the use of the National Priority Voucher Program for this approval suggests a strategic emphasis on metabolic health treatments. Organizations may need to monitor post-market data specifically regarding titration and safety profiles associated with this higher dosage strength.
Regulatory and clinical teams should update labeling, dosage instructions, and patient monitoring protocols to reflect the 7.2 mg dose. Pharmacovigilance departments should incorporate the higher dosage into signal detection and risk management strategies. Quality and manufacturing teams must ensure production specifications align with the newly approved dosage strength.
The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.
Open in openFDA / FDA.gov